vs
Side-by-side financial comparison of Beta Bionics, Inc. (BBNX) and Clearfield, Inc. (CLFD). Click either name above to swap in a different company.
Clearfield, Inc. is the larger business by last-quarter revenue ($34.3M vs $27.6M, roughly 1.2× Beta Bionics, Inc.). Clearfield, Inc. runs the higher net margin — -1.8% vs -79.3%, a 77.5% gap on every dollar of revenue. On growth, Beta Bionics, Inc. posted the faster year-over-year revenue change (56.6% vs -3.2%).
Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.
Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.
BBNX vs CLFD — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $34.3M |
| Net Profit | $-21.9M | $-614.0K |
| Gross Margin | 59.5% | 33.2% |
| Operating Margin | -47.4% | -5.3% |
| Net Margin | -79.3% | -1.8% |
| Revenue YoY | 56.6% | -3.2% |
| Net Profit YoY | 23.6% | 67.8% |
| EPS (diluted) | $-0.49 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.6M | — | ||
| Q4 25 | $32.1M | $34.3M | ||
| Q3 25 | $27.3M | $23.4M | ||
| Q2 25 | $23.2M | $49.9M | ||
| Q1 25 | $17.6M | $47.2M | ||
| Q4 24 | — | $29.7M | ||
| Q3 24 | — | $5.6M | ||
| Q2 24 | — | $48.8M |
| Q1 26 | $-21.9M | — | ||
| Q4 25 | $-13.5M | $-614.0K | ||
| Q3 25 | $-14.2M | $-9.1M | ||
| Q2 25 | $-16.9M | $1.6M | ||
| Q1 25 | $-28.7M | $1.3M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-447.0K |
| Q1 26 | 59.5% | — | ||
| Q4 25 | 59.0% | 33.2% | ||
| Q3 25 | 55.5% | 53.2% | ||
| Q2 25 | 53.8% | 30.5% | ||
| Q1 25 | 50.9% | 30.1% | ||
| Q4 24 | — | 29.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 21.9% |
| Q1 26 | -47.4% | — | ||
| Q4 25 | -50.2% | -5.3% | ||
| Q3 25 | -62.5% | 10.3% | ||
| Q2 25 | -85.5% | 3.0% | ||
| Q1 25 | -105.7% | 0.6% | ||
| Q4 24 | — | -6.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -4.7% |
| Q1 26 | -79.3% | — | ||
| Q4 25 | -41.9% | -1.8% | ||
| Q3 25 | -52.1% | -38.8% | ||
| Q2 25 | -72.6% | 3.2% | ||
| Q1 25 | -162.5% | 2.8% | ||
| Q4 24 | — | -6.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.9% |
| Q1 26 | $-0.49 | — | ||
| Q4 25 | $-0.16 | $-0.04 | ||
| Q3 25 | $-0.33 | $-0.65 | ||
| Q2 25 | $-0.39 | $0.11 | ||
| Q1 25 | $-0.93 | $0.09 | ||
| Q4 24 | — | $-0.13 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $199.5M | $96.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $271.2M | $249.7M |
| Total Assets | $304.4M | $268.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $199.5M | — | ||
| Q4 25 | $219.1M | $96.4M | ||
| Q3 25 | $228.7M | $106.0M | ||
| Q2 25 | $249.7M | $117.2M | ||
| Q1 25 | $231.5M | $112.0M | ||
| Q4 24 | — | $113.0M | ||
| Q3 24 | — | $129.0M | ||
| Q2 24 | — | $123.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $2.2M | ||
| Q2 24 | — | $2.1M |
| Q1 26 | $271.2M | — | ||
| Q4 25 | $287.6M | $249.7M | ||
| Q3 25 | $294.8M | $256.2M | ||
| Q2 25 | $301.6M | $264.5M | ||
| Q1 25 | $313.8M | $265.9M | ||
| Q4 24 | — | $267.4M | ||
| Q3 24 | — | $275.8M | ||
| Q2 24 | — | $274.6M |
| Q1 26 | $304.4M | — | ||
| Q4 25 | $328.7M | $268.1M | ||
| Q3 25 | $330.0M | $306.2M | ||
| Q2 25 | $330.0M | $314.7M | ||
| Q1 25 | $338.0M | $310.9M | ||
| Q4 24 | — | $303.2M | ||
| Q3 24 | — | $315.3M | ||
| Q2 24 | — | $318.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.4M |
| Free Cash FlowOCF − Capex | — | $-2.4M |
| FCF MarginFCF / Revenue | — | -7.1% |
| Capex IntensityCapex / Revenue | — | 2.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-8.6M | $-1.4M | ||
| Q3 25 | $-8.7M | — | ||
| Q2 25 | $-13.6M | $7.9M | ||
| Q1 25 | $-20.0M | $3.0M | ||
| Q4 24 | — | $7.2M | ||
| Q3 24 | — | $22.2M | ||
| Q2 24 | — | $4.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-10.5M | $-2.4M | ||
| Q3 25 | $-10.0M | — | ||
| Q2 25 | $-15.4M | $7.5M | ||
| Q1 25 | $-20.3M | $654.0K | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | — | $18.2M | ||
| Q2 24 | — | $2.8M |
| Q1 26 | — | — | ||
| Q4 25 | -32.8% | -7.1% | ||
| Q3 25 | -36.7% | — | ||
| Q2 25 | -66.2% | 15.1% | ||
| Q1 25 | -115.1% | 1.4% | ||
| Q4 24 | — | 17.1% | ||
| Q3 24 | — | 323.0% | ||
| Q2 24 | — | 5.8% |
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | 2.9% | ||
| Q3 25 | 4.7% | 2.0% | ||
| Q2 25 | 7.7% | 0.8% | ||
| Q1 25 | 1.9% | 5.1% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 71.4% | ||
| Q2 24 | — | 2.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 4.93× | ||
| Q1 25 | — | 2.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
